Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kei Muro
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients With Gastrointestinal Cancer
Oncologist
Cancer Research
Medicine
Oncology
Large‐Scale, Prospective Observational Study of Regorafenib in Japanese Patients With Metastatic Colorectal Cancer in a Real‐World Clinical Setting
Oncologist
Cancer Research
Medicine
Oncology
A Phase 3 Study of Nivolumab in Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (ATTRACTION-2): 2-Year Update Data
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
Exploratory Subgroup Analysis of Patients With Prior Trastuzumab Use in the ATTRACTION-2 Trial: A Randomized Phase III Clinical Trial Investigating the Efficacy and Safety of Nivolumab in Patients With Advanced Gastric/Gastroesophageal Junction Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
Clinical Features of Regorafenib-Induced Liver Injury in Japanese Patients From Post-Marketing Experience
Clinical Colorectal Cancer
Oncology
Gastroenterology
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of Two Randomized Clinical Trials
Clinical Colorectal Cancer
Oncology
Gastroenterology
TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
A Phase II Trial of Ixabepilone in Asian Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine-Based Chemotherapy
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase 1 Pharmacokinetic Study of MK-0646 (Dalotuzumab), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Combination With Cetuximab and Irinotecan in Japanese Patients With Advanced Colorectal Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
1
2
›